Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

IDOL regulates systemic energy balance through control of neuronal VLDLR expression.

Lee SD, Priest C, Bjursell M, Gao J, Arneson DV, Ahn IS, Diamante G, van Veen JE, Massa MG, Calkin AC, Kim J, Andersén H, Rajbhandari P, Porritt M, Carreras A, Ahnmark A, Seeliger F, Maxvall I, Eliasson P, Althage M, Åkerblad P, Lindén D, Cole TA, Lee R, Boyd H, Bohlooly-Y M, Correa SM, Yang X, Tontonoz P, Hong C.

Nat Metab. 2019 Nov;1(11):1089-1100. doi: 10.1038/s42255-019-0127-7. Epub 2019 Oct 28.

PMID:
32072135
2.

The Antioxidant Moiety of MitoQ Imparts Minimal Metabolic Effects in Adipose Tissue of High Fat Fed Mice.

Bond ST, Kim J, Calkin AC, Drew BG.

Front Physiol. 2019 May 8;10:543. doi: 10.3389/fphys.2019.00543. eCollection 2019.

3.

An integrative systems genetic analysis of mammalian lipid metabolism.

Parker BL, Calkin AC, Seldin MM, Keating MF, Tarling EJ, Yang P, Moody SC, Liu Y, Zerenturk EJ, Needham EJ, Miller ML, Clifford BL, Morand P, Watt MJ, Meex RCR, Peng KY, Lee R, Jayawardana K, Pan C, Mellett NA, Weir JM, Lazarus R, Lusis AJ, Meikle PJ, James DE, de Aguiar Vallim TQ, Drew BG.

Nature. 2019 Mar;567(7747):187-193. doi: 10.1038/s41586-019-0984-y. Epub 2019 Feb 27.

4.

The E3 ligase MARCH5 is a PPARγ target gene that regulates mitochondria and metabolism in adipocytes.

Bond ST, Moody SC, Liu Y, Civelek M, Villanueva CJ, Gregorevic P, Kingwell BA, Hevener AL, Lusis AJ, Henstridge DC, Calkin AC, Drew BG.

Am J Physiol Endocrinol Metab. 2019 Feb 1;316(2):E293-E304. doi: 10.1152/ajpendo.00394.2018. Epub 2018 Dec 4.

5.

The CCC Complex COMManDs Control of LDL Cholesterol Levels.

Keating MF, Calkin AC.

Circ Res. 2018 Jun 8;122(12):1629-1631. doi: 10.1161/CIRCRESAHA.118.313074. No abstract available.

PMID:
29880494
6.

Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets.

Ju L, McFadyen JD, Al-Daher S, Alwis I, Chen Y, Tønnesen LL, Maiocchi S, Coulter B, Calkin AC, Felner EI, Cohen N, Yuan Y, Schoenwaelder SM, Cooper ME, Zhu C, Jackson SP.

Nat Commun. 2018 Mar 14;9(1):1087. doi: 10.1038/s41467-018-03430-6.

7.

Thrombosis in diabetes: a shear flow effect?

Westein E, Hoefer T, Calkin AC.

Clin Sci (Lond). 2017 Jun 15;131(12):1245-1260. doi: 10.1042/CS20160391. Review.

PMID:
28592700
8.

Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.

Ritchie RH, Zerenturk EJ, Prakoso D, Calkin AC.

J Mol Endocrinol. 2017 May;58(4):R225-R240. doi: 10.1530/JME-16-0249. Epub 2017 Apr 3. Review.

PMID:
28373293
9.

The Use of L-sIDOL Transgenic Mice as a Murine Model to Study Hypercholesterolemia and Atherosclerosis.

Zerenturk EJ, Calkin AC.

Methods Mol Biol. 2017;1583:65-72. doi: 10.1007/978-1-4939-6875-6_6.

PMID:
28205167
10.

Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling.

Gray SP, Di Marco E, Kennedy K, Chew P, Okabe J, El-Osta A, Calkin AC, Biessen EA, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):295-307. doi: 10.1161/ATVBAHA.115.307012. Epub 2015 Dec 29.

PMID:
26715682
11.

Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.

Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL.

J Biol Chem. 2015 Feb 27;290(9):5566-81. doi: 10.1074/jbc.M114.606459. Epub 2014 Dec 2.

12.

Transgenic expression of dominant-active IDOL in liver causes diet-induced hypercholesterolemia and atherosclerosis in mice.

Calkin AC, Lee SD, Kim J, Van Stijn CM, Wu XH, Lusis AJ, Hong C, Tangirala RI, Tontonoz P.

Circ Res. 2014 Aug 1;115(4):442-9. doi: 10.1161/CIRCRESAHA.115.304440. Epub 2014 Jun 16.

13.

Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Watson AM, Olukman M, Koulis C, Tu Y, Samijono D, Yuen D, Lee C, Behm DJ, Cooper ME, Jandeleit-Dahm KA, Calkin AC, Allen TJ.

Diabetologia. 2013 May;56(5):1155-65. doi: 10.1007/s00125-013-2837-9. Epub 2013 Jan 24.

PMID:
23344731
14.

Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

Calkin AC, Tontonoz P.

Nat Rev Mol Cell Biol. 2012 Mar 14;13(4):213-24. doi: 10.1038/nrm3312. Review.

15.

FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors.

Calkin AC, Goult BT, Zhang L, Fairall L, Hong C, Schwabe JW, Tontonoz P.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20107-12. doi: 10.1073/pnas.1111589108. Epub 2011 Nov 22.

16.

The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans.

Weissglas-Volkov D, Calkin AC, Tusie-Luna T, Sinsheimer JS, Zelcer N, Riba L, Tino AM, Ordoñez-Sánchez ML, Cruz-Bautista I, Aguilar-Salinas CA, Tontonoz P, Pajukanta P.

J Clin Invest. 2011 Aug;121(8):3062-71. doi: 10.1172/JCI45504. Epub 2011 Jul 18.

17.

The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor.

Zhang L, Fairall L, Goult BT, Calkin AC, Hong C, Millard CJ, Tontonoz P, Schwabe JW.

Genes Dev. 2011 Jun 15;25(12):1262-74. doi: 10.1101/gad.2056211.

18.

Large artery biomechanics and diastolic dysfunctionin patients with Type 2 diabetes.

Soldatos G, Jandeleit-Dahm K, Thomson H, Formosa M, D'orsa K, Calkin AC, Cooper ME, Ahimastos AA, Kingwell BA.

Diabet Med. 2011 Jan;28(1):54-60. doi: 10.1111/j.1464-5491.2010.03146.x.

PMID:
21166846
19.

Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice.

Watson AM, Soro-Paavonen A, Sheehy K, Li J, Calkin AC, Koitka A, Rajan SN, Brasacchio D, Allen TJ, Cooper ME, Thomas MC, Jandeleit-Dahm KJ.

Diabetologia. 2011 Mar;54(3):681-9. doi: 10.1007/s00125-010-2000-9. Epub 2010 Dec 14.

PMID:
21161164
20.

Genome-wide association studies identify new targets in cardiovascular disease.

Calkin AC, Tontonoz P.

Sci Transl Med. 2010 Sep 8;2(48):48ps46. doi: 10.1126/scitranslmed.3001557.

PMID:
20826839
21.

Liver x receptor signaling pathways and atherosclerosis.

Calkin AC, Tontonoz P.

Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1513-8. doi: 10.1161/ATVBAHA.109.191197. Review.

22.

The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.

Giunti S, Calkin AC, Forbes JM, Allen TJ, Thomas MC, Cooper ME, Jandeleit-Dahm KA.

Am J Physiol Renal Physiol. 2010 Sep;299(3):F528-35. doi: 10.1152/ajprenal.00127.2010. Epub 2010 Jun 16.

23.

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux.

Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP.

Circulation. 2009 Nov 24;120(21):2095-104. doi: 10.1161/CIRCULATIONAHA.109.870709. Epub 2009 Nov 9.

PMID:
19901191
24.

Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis.

Pham Y, Tu Y, Wu T, Allen TJ, Calkin AC, Watson AM, Li J, Jandeleit-Dahm KA, Toh BH, Cao Z, Cooper ME, Chai Z.

Diabetologia. 2010 Jan;53(1):170-9. doi: 10.1007/s00125-009-1555-9. Epub 2009 Oct 22.

PMID:
19847393
25.

Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.

Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, El-Osta A.

Diabetes. 2009 May;58(5):1229-36. doi: 10.2337/db08-1666. Epub 2009 Feb 10.

26.

The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

Calkin AC, Giunti S, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA.

Diabetologia. 2008 Sep;51(9):1731-40. doi: 10.1007/s00125-008-1060-6. Epub 2008 Jul 2.

PMID:
18594792
27.

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes.

Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA.

Diabetes. 2008 Sep;57(9):2461-9. doi: 10.2337/db07-1808. Epub 2008 May 28.

28.

PPAR Agonists and Cardiovascular Disease in Diabetes.

Calkin AC, Thomas MC.

PPAR Res. 2008;2008:245410. doi: 10.1155/2008/245410.

29.

PPARs and diabetes-associated atherosclerosis.

Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, Tikellis C.

Curr Pharm Des. 2007;13(26):2736-41. Review.

PMID:
17897018
30.

The clot thickens--oxidized lipids and thrombosis.

Jackson SP, Calkin AC.

Nat Med. 2007 Sep;13(9):1015-6. No abstract available.

PMID:
17828215
31.

Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.

Drew BG, Calkin AC.

Curr Opin Investig Drugs. 2007 Apr;8(4):324-30. Review.

PMID:
17458183
32.

Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.

Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB.

Circulation. 2007 Apr 24;115(16):2178-87. Epub 2007 Apr 9.

PMID:
17420349
33.

Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.

Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC.

Atherosclerosis. 2007 Nov;195(1):17-22. Epub 2007 Jan 9.

PMID:
17214990
34.

PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.

Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC.

Nephrol Dial Transplant. 2006 Sep;21(9):2399-405. Epub 2006 May 23.

PMID:
16720596
35.
36.

Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.

Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Diabetologia. 2006 Apr;49(4):766-74. Epub 2006 Feb 4.

PMID:
16463048
37.

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.

Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1903-9. Epub 2005 Jul 14.

PMID:
16020748
38.

Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.

Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME.

J Am Soc Nephrol. 2005 Feb;16(2):363-73. Epub 2004 Dec 29.

39.

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA.

J Am Soc Nephrol. 2004 Aug;15(8):2125-38.

40.

MK-767. Kyorin/Banyu/Merck.

Calkin AC, Thomas MC, Cooper ME.

Curr Opin Investig Drugs. 2003 Apr;4(4):444-8. Review.

PMID:
12808885
41.

Rapid potentiation of endothelium-dependent vasodilation by estradiol in postmenopausal women is mediated via cyclooxygenase 2.

Calkin AC, Sudhir K, Honisett S, Williams MR, Dawood T, Komesaroff PA.

J Clin Endocrinol Metab. 2002 Nov;87(11):5072-5.

PMID:
12414874

Supplemental Content

Loading ...
Support Center